Originating from research on glasswort, a salt marsh plant, this technology utilizes laminarin as an active ingredient in pharmaceutical and food compositions to prevent and treat sarcopenia caused by chemotherapy. Laminarin inhibits the increase of myostatin mRNA and protein triggered by the anticancer drug bleomycin.
Sarcopenia, a condition where muscle mass decreases by approximately 8% every decade after age 40 and up to 15% after age 70, is rising rapidly alongside an aging population. Exercise is inadequate as a long-term treatment, while testosterone or anabolic steroids carry side effects like masculinization in women or prostate issues in men. Dietary changes alone struggle to maintain muscle mass, and there has been a lack of safe substances that fundamentally inhibit myostatin, the direct driver of muscle loss.
This technology uses laminarin to block the expression of myostatin, which inhibits protein synthesis and proliferation in myoblasts, while also reducing UV-induced myostatin and the expression of MURF1, which is involved in muscle degradation. It can be applied to adjuvant therapies for managing muscle loss in cancer patients, specialized medical foods for nutritional support, and health supplements for maintaining muscle strength in the elderly, helping to preserve muscle mass, physical stamina, and treatment adherence.
This invention was developed with support from the Ministry of Oceans and Fisheries for research on discovering and commercializing potential marine healing resources to revitalize the marine industry.
This technology utilizes CaSIMK1, a MAP3 kinase protein (SEQ ID NO: 2) identified in the Nokgwang chili pepper cultivar that interacts with SnRK2.6—a key kinase in ABA signaling—as an active ingredient for compositions and kits designed to improve drought stress resistance, as well as methods for enhancing drought tolerance by increasing the expression or activity of this protein.
While crop yield losses due to drought are intensifying, the individual kinases involved in the process—where ABA receptors recognize signals and trigger downstream genes and ion channels through protein phosphorylation—have not been fully characterized. Consequently, although research on drought-tolerance genes and transgenic plants has been ongoing, there remains a shortage of signaling-pathway gene resources suitable for practical crop improvement.
Based on the discovery that CaSIMK1 acts as a positive regulator that strengthens the ABA signaling phosphorylation cascade by interacting with SnRK2.6, this technology is configured to use the protein encoded by the gene in SEQ ID NO: 1 as a composition or to produce transgenic chili pepper and Arabidopsis plants with increased expression. It can be applied to breeding chili peppers and solanaceous crops in drought-prone regions, developing ABA-signaling-enhanced drought-tolerant transgenic plants, and supporting seed companies' climate-adaptive variety pipelines, thereby amplifying the phosphorylation stage of ABA signaling to strengthen defense responses against water scarcity and reduce crop losses during droughts.
This invention was developed with support from the Ministry of Science and ICT for research on drought and salt tolerance signaling through protein stabilization regulation in chili peppers.
This technology provides a composition and kit for enhancing drought stress resistance, containing the homeobox-family ABA-responsive transcription factor CaHAT1 protein (SEQ ID NO: 2) isolated from the Nokgwang pepper cultivar, as well as a method for increasing plant drought tolerance by enhancing the expression or activity of this protein.
As desertification and water scarcity place significant burdens on agriculture and the environment, there is a growing need for crops that can thrive with less water. While it is known that plants unable to produce or respond to ABA are vulnerable to stress, the development of resistant plants using individual proteins involved in ABA response has been limited. In particular, there has been a lack of useful crop-derived genes at the transcription factor level that directly activate downstream gene expression in response to ABA signals.
This technology leverages the fact that CaHAT1 acts as a positive regulator of ABA signaling. It is configured to include the protein encoded by the gene of SEQ ID NO: 1 in a composition or to produce transgenic pepper and Arabidopsis plants with increased expression levels. Applicable to open-field pepper cultivation where irrigation is difficult, the development of drought-tolerant vegetable varieties for semi-arid regions, and the breeding of plants for greening arid areas, it allows for the creation of crops that reduce transpiration and maintain growth during drought by regulating the expression of a single transcription factor.
This invention was developed with support from the Ministry of Science and ICT for research on drought and salt tolerance signaling through protein stabilization regulation in chili peppers.
본 기술은 출하 직전 약 3개월 동안 거세 한우에 급여하는 비육 말기 사료로, 기존 배합에 대두박을 늘리거나 대두박과 옥수수주정박(DDGS)을 함께 늘려 제1제한 아미노산인 라이신과 대사 단백질 공급량을 높인 두 가지 배합 조성물입니다.
국내 한우사양표준은 단백질 공급량을 조단백질 수준으로만 제시할 뿐, 반추위 미생물 단백질과 소장으로 넘어가는 미분해 사료 단백질의 아미노산 공급량을 기준으로 사료를 설계하지 않았습니다. 이 때문에 근육 단백질 합성에 필요한 필수아미노산이 부족하거나 남아도 보완할 방법이 없어 육량 개선에 한계가 있었고, 사료가 낭비되며 과잉 질소가 배출되어 환경을 오염시키는 문제가 있었습니다.
본 기술은 대두박 6.0중량% 배합과, 대두박 4.0중량%에 옥수수주정박 4.6중량%를 더한 배합을 제시하며, 이를 통해 라이신을 하루 약 4g, 대사 단백질을 사료 kg당 6.7~8.9g 더 공급합니다. 시험 결과 도체중이 440.5kg에서 최대 467.5kg으로, 등심면적이 96.2cm²에서 98.0cm²로 늘었고 혈중 요소가 줄며 풍미 인자인 혈중 글루타민산이 증가했습니다. 한우 비육농가의 출하 전 마무리 사료, 배합사료 업체의 고급육 전용 제품, 저질소 배출형 친환경 축산 사양 프로그램에 적용될 수 있어 아미노산 이용 효율을 높여 도체중과 고기 풍미를 함께 끌어올리면서 질소 배출량은 줄일 수 있습니다.
본 발명은 농림축산식품부의 한우 근내 풍미 증진을 위한 유용 아미노산 조성 반추가축 사료 및 첨가제 개발 지원을 통해 개발되었습니다.
This technology is a pharmaceutical composition for the prevention and treatment of obesity, featuring capmatinib—a c-Met inhibitor used to treat non-small cell lung cancer with MET exon 14 skipping mutations—as its active ingredient. This compound prevents lipid accumulation in adipocytes and inhibits fat synthesis while simultaneously breaking down triglycerides into fatty acids and glycerol.
Obesity is a state where energy intake exceeds expenditure, causing excess energy to be stored as body fat. Research indicates that higher body mass indices correlate with increased prevalence of 17 out of 20 studied cancers, including leukemia, pancreatic, breast, colorectal, and liver cancer. However, there has been no drug capable of simultaneously treating cancer and suppressing obesity, making it difficult to preemptively block obesity-related cancer development.
This technology leverages capmatinib’s ability to inhibit the expression of proteins involved in fat synthesis—SREBP1, C/EBPα, FAS, and SCD1—and increase glycerol release. It is formulated to exert an anti-adipogenic effect at concentrations of 0.3–1.5 nM, which is below the 2 nM threshold for cytotoxicity. It can be formulated in various ways, from oral forms like tablets and capsules to injections and suppositories. Applicable to new anti-obesity drug development, preventive therapy for high-risk cancer groups with obesity, and expanding indications for existing anticancer drugs, this approach repurposes a clinically proven targeted therapy to reduce development time while managing both obesity and related cancer risks.
This invention was developed with support from the Ministry of Science and ICT for research on the therapeutic effects of the endogenous metabolite kynurenic acid on non-alcoholic fatty liver disease through the amelioration of endoplasmic reticulum stress.
This technology features a pharmaceutical composition for the prevention and treatment of hyperlipidemia and fatty liver, as well as a food composition for improvement, containing peptides of SEQ ID NO: 1 or 2 derived from the adipokine LGI3 protein secreted by adipose tissue. In animal models, it has been shown to effectively reduce blood cholesterol, low-density lipoprotein (LDL), liver triglycerides, and liver cholesterol.
While statins dominate over half the market for hyperlipidemia treatment, they are associated with various side effects. For fatty liver, there is a significant unmet need as no clear treatment exists beyond lifestyle changes, often leading to the off-label use of diabetes medications or hepatoprotective agents. Furthermore, LGI3 is a large protein of 548 amino acids (approx. 60 kDa), making direct human application difficult, and its potential for treating hyperlipidemia and fatty liver through activity modulation was previously unknown.
Instead of using the large protein, this technology utilizes LGI3-derived peptides suitable for human application to modulate LGI3 bioactivity, targeting various fatty liver diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. It can be applied as a statin alternative or combination therapy for hyperlipidemia, a drug candidate for NASH, or a health functional food for cholesterol management. This offers a peptide-based metabolic disease treatment option that lowers both blood and liver lipids while reducing the burden of side effects associated with existing therapies.
This invention was developed with support from the Ministry of Education for research on the in vivo activity modulation of the cytokine LGI3.
This technology involves the newly identified pepper SUMO E3 ligase gene CaSIZ1 (SEQ ID NO: 2), a recombinant vector containing it, and a method for enhancing drought stress resistance by transforming and overexpressing this gene in plants. CaSIZ1 acts as a positive regulator of ABA signaling, helping plants better withstand drought conditions.
Drought significantly impairs plant growth, leading to reduced crop yields. While plants respond by closing stomata and accumulating abscisic acid (ABA), the complete ABA signaling pathway remains unclear. Although protein sumoylation is known to be linked to stress responses and the role of Arabidopsis SIZ1 has been partially reported, the specific mechanisms by which SUMO E3 ligases contribute to drought resistance via the ABA pathway, as well as genes applicable to crops, have remained largely unavailable.
This technology utilizes the mechanism by which CaSIZ1 sumoylates and stabilizes the CaDRHB1 protein, a negative regulator of ABA signaling. It confers resistance through two stages: using the gene alone or in a recombinant vector as an active ingredient, and then overexpressing the protein after transformation. Applicable to breeding drought-resistant pepper varieties, developing transgenic crops for arid regions, and water-efficient greenhouse cultivation, it targets the post-translational regulation step of sumoylation to maintain crop survival and productivity in water-scarce environments.
This invention was developed with support from the Rural Development Administration's research on ABA signaling stabilization protein molecules and their physiological mechanisms.
This technology uses EEAA, an ethanol extract of dried hardy kiwi fruit (Actinidia arguta), as an active ingredient to induce muscle cells to convert directly into adipocytes or adipocyte-like cells instead of developing into myotubes. When applied to C2C12 myoblasts, it was confirmed that myotube formation decreased while lipid accumulation, stained red with Oil Red O, increased.
Muscle and fat cells originate from the same embryonic stem cells and are capable of transdifferentiation, but research on natural materials to regulate this process has been limited. Furthermore, while the anti-cancer and antioxidant effects of hardy kiwi are known, its ability to regulate transdifferentiation had not been reported. In particular, lab-grown meat lacks intramuscular fat, failing to replicate the flavor and tenderness of real meat, and currently requires the artificial addition of fat after muscle growth.
This technology shifts the differentiation of myoblasts toward fat by lowering the expression of MyoD, a key marker for muscle differentiation, and increasing the expression of adipogenic markers such as C/EBP-β, C/EBP-α, and PPAR-γ, all while operating at non-cytotoxic concentrations. It can be applied to produce cultured meat with naturally occurring intramuscular fat, as a feed additive to improve marbling in Hanwoo beef, and as a cell model for studying ectopic fat in muscle. This allows for the creation of high-value artificial meat with flavor and texture closer to real meat by generating fat tissue directly during the culture phase.
This invention was developed with support from the Ministry of Education for the development of traditional Korean medicine treatment technologies and mechanism research regarding photoaging.
This technology is a pharmaceutical composition for the prevention and treatment of Alzheimer's disease, as well as a health functional food composition for prevention and improvement, containing a complex of five ginsenosides—Gypenoside LXXV (G75), Rk2, C-Mx, Protopanaxadiol (PPD), and Rg5—as active ingredients. This complex prevents the death of nerve cells caused by beta-amyloid toxicity.
Alzheimer's disease is a progressive degenerative brain disorder characterized by the sequential damage of the hippocampus, forebrain, and temporal lobe, leading to the loss of 30–40% of neurons. The neurotoxicity of beta-amyloid, the primary component of senile plaques, has been identified as a major cause. While activated microglia release inflammatory cytokines, nitric oxide, and reactive oxygen species that damage nerves, normal microglia play a role in clearing beta-amyloid. Therefore, there has been a need for neuroprotective substances that ensure microglial survival, which have not been sufficiently identified until now.
This technology confirms that each of the five ginsenosides protects microglia from beta-amyloid and shields nerve cells from oxidative stress, with their combined use producing a synergistic effect in neuroprotection. It can be applied to natural drug candidates for patients with mild cognitive impairment or early-stage Alzheimer's, functional red ginseng ingredients for memory improvement, and brain health supplements for the elderly. By combining rare ginseng-derived ginsenosides in an optimal ratio, it achieves higher neuroprotective effects than single components with a lower risk of side effects.
This invention was developed with support from the Ministry of Education's research on the effects of ginseng ginsenosides on microglial cell viability and neuroinflammatory responses.
This technology is a composition for the prevention and treatment of viral infectious diseases, containing a complex of 3-MA or chloroquine (ROS production inhibitors) and SOD1 (a superoxide dismutase ROS scavenger) as active ingredients. This complex can also be provided as a food composition, feed additive, disinfectant, or cosmetic composition.
Respiratory viruses like influenza A activate endoplasmic reticulum stress and autophagy upon infection, hindering ROS removal by degrading antioxidant proteins such as SOD. This leads to cytokine storms, cell death, and severe oxidative damage. Existing vaccines are limited by their specificity to certain viruses, requiring new development for every mutation.
This technology uses production inhibitors to block ROS generation by suppressing ER stress and autophagy, while SOD1 scavenges existing ROS. Additional scavengers like N-acetylcysteine, glutathione, catalase, or BHA can be added, and the composition can be formulated for nasal or oral inhalation. It can be applied as an adjuvant for influenza, COVID-19, or HIV treatment, a universal prophylactic inhalant for new viral outbreaks, or a feed additive for livestock disease control. By exploiting the mechanism where viruses use host oxidative damage to replicate, it inhibits viral growth regardless of type or mutation while reducing tissue damage.
This technology involves a pharmaceutical composition and health functional food for pain suppression and prevention, containing BigLEN (SEQ ID NO: 1 or 2, e.g., LENPSPEAPARRLLPP), a brain-abundant neuropeptide, or its pharmaceutically acceptable salts as an active ingredient. BigLEN exhibits analgesic effects that suppress hyperalgesia induced by various stimuli.
Current analgesics are largely divided into non-steroidal anti-inflammatory drugs (NSAIDs)/COX-2 inhibitors and opioids like morphine, both of which have shown little efficacy for neuropathic pain. Opioids show some effect only at high doses but carry risks of severe side effects and addiction, while NSAIDs require higher doses for efficacy, leading to gastrointestinal side effects.
This technology is based on the confirmation that the L-amino acid-based BigLEN peptide reduces pain in models of formalin-induced pain, CFA-induced inflammatory hyperalgesia, mechanical/thermal hyperalgesia, and neuropathic pain. Target conditions include postoperative pain, cancer pain, chemotherapy-induced pain, postherpetic neuralgia, fibromyalgia, and migraines. It can be applied to chemotherapy-induced peripheral neuropathy analgesics, non-narcotic injections for postoperative pain, and health supplements for chronic pain, addressing neuropathic pain that existing drugs cannot treat without the addiction risks of opioids or the GI issues of NSAIDs.
This invention was developed with support from the Ministry of Science and ICT for the development of core technologies for pain control and assessment based on input neural network molecular mechanisms.
This technology provides a composition, coating composition, and inhibition method that uses the FDA-approved histone deacetylase inhibitor SAHA (vorinostat) as an active ingredient to suppress biofilm formation by Salmonella species. The composition can be applied or coated onto food surfaces such as chicken skin and eggshells, food-contact surfaces like glass, rubber, silicone, and plastic, and medical devices.
Salmonella is a zoonotic pathogen that causes sepsis, diarrhea, and pneumonia, with increasing rates of antibiotic resistance. It forms biofilms on the surfaces of medical devices and food processing equipment made of stainless steel, plastic, and rubber, making it difficult to remove even with antimicrobial agents. Treatments such as electric fields, ultrasound, and high pressure have shown minimal sterilization effects, are limited in application area, and are costly. Furthermore, acid-base cleaning solutions and chlorine-based disinfectants cause metal corrosion, produce carcinogens like trihalomethanes, and pose risks of recontamination due to the reuse of wash water.
This technology utilizes SAHA at a minimum inhibitory concentration of 120 μg/mL to inhibit the swimming and swarming motility of S. enterica and downregulates the expression of genes related to pathogenicity and quorum sensing, preventing biofilm establishment. It can be applied to surface hygiene management in poultry processing and egg grading plants, coating rubber and silicone parts in food processing equipment, and preventing infections on medical implants like catheters. This allows for blocking the attachment phase of Salmonella using a drug with proven safety, eliminating the need for corrosive disinfectants or large volumes of wash water.
This invention was developed with research support from the Ministry of Science and ICT for identifying the causes of pathogenic bacterial biofilm formation in the food industry and developing efficient control technologies that combine physical, chemical, and biological techniques.
This technology enhances both drought and salt stress resistance in plants by inhibiting the expression or activity of CaFIRF1 (a RING finger protein that interacts with FAF1), identified in chili peppers. Since CaFIRF1 acts as a negative regulator that reduces plant tolerance under drought and high-salinity conditions, silencing it strengthens resistance to both abiotic stresses.
Global warming and desertification have increased drought and soil salinity, severely threatening crop productivity, yet the signaling pathway of ABA, a key plant defense hormone, remains incompletely understood. While it was known that E3 ligases responsible for ubiquitination regulate stress responses, there has been a lack of RING finger genes in chili peppers that simultaneously regulate drought and salt stress, as well as practical means to target them for improvement.
This technology involves using the CRISPR-Cas9 gene-editing system to inhibit the expression of the CaFIRF1 protein (SEQ ID NO: 1). The resulting transgenic chili pepper plants exhibit improved tolerance to both water scarcity and saline environments. Applicable to developing chili varieties for reclaimed or coastal saline soils, open-field cultivation in drought-prone areas, and gene-editing-based breeding of stress-tolerant vegetables, this method overcomes two major cultivation limitations simultaneously by editing a single endogenous gene without introducing foreign DNA.
This invention was developed with support from the Ministry of Science and ICT for research on drought and salt tolerance signaling through protein stabilization regulation in chili peppers.
This technology is based on the discovery that the RING finger protein gene CaGIR1 in peppers acts as a negative regulator that suppresses drought stress tolerance. By inhibiting the expression or protein activity of this gene, we can enhance a plant's drought resistance. The expression inhibitor used is a recombinant VIGS vector containing CaGIR1 cDNA.
As global warming and desertification exacerbate water shortages, drought has become a primary cause of stunted crop growth and significant yield loss. While plants respond to dehydration through stomatal closure and abscisic acid (ABA) accumulation, the ABA signaling pathway is not fully understood, and research into drought-related genes and their application in transgenic plants remains limited.
This technology confirms that suppressing the CaGIR1 protein (SEQ ID NO: 1) via Virus-Induced Gene Silencing (VIGS) allows plants to better withstand water-deficient conditions. Transgenic plants with enhanced drought resistance can be developed in peppers or Arabidopsis. This approach can be applied to breeding drought-tolerant pepper varieties, improving horticultural crops in greenhouses or open fields where water usage must be minimized, and developing plants for greening arid regions. By silencing a single gene, we can reduce reliance on irrigation and ensure stable yields even during droughts.
This invention was developed with support from the Ministry of Science and ICT for research on drought and salt tolerance signaling through protein stabilization regulation in chili peppers.
This technology involves a method for producing fruit black tea by drying 0.5–1 cm thick slices of kiwi, lemon, and tangerine at 45°C for 72 hours, then blending 150 parts by weight of dried black tea leaves with 120 parts dried tangerine, 20 parts kiwi, and 10 parts lemon. The dried fruit complements the tea's natural aroma, adding a subtle, authentic fruit flavor.
Black tea contains more caffeine than green or oolong tea, and the high concentration of polyphenol polymers released during brewing often results in a harsh, astringent taste that can be off-putting. To mask this, many products rely on artificial flavorings. Meanwhile, the domestic tea industry faces a surplus of second-flush tea—often considered lower quality than the first flush—and farmers struggle with falling prices for tangerines and kiwis due to overproduction.
This technology processes second-flush tea leaves through sun-withering for 3 hours, indoor withering at 10–20°C for 20 hours, rolling for 40 minutes, three 40-minute fermentation cycles at 40°C, and 6 hours of sun-fermentation before drying. By blending these leaves with low-temperature, long-dried fruits in precise ratios, the tea's astringency and bitterness are significantly reduced. Suitable for premium fruit tea bags, regional gift sets, and unsweetened cafe bases, this method helps consume surplus tea and fruit, boosts farm income in regions like Jeonnam, and provides a smooth, natural tea experience without artificial additives.
This invention was developed with support from the Ministry of Education's Bio-Convergence Human Resources Development Program.
